CN116249774A - 核酸人工微型蛋白质组文库 - Google Patents
核酸人工微型蛋白质组文库 Download PDFInfo
- Publication number
- CN116249774A CN116249774A CN202180048206.XA CN202180048206A CN116249774A CN 116249774 A CN116249774 A CN 116249774A CN 202180048206 A CN202180048206 A CN 202180048206A CN 116249774 A CN116249774 A CN 116249774A
- Authority
- CN
- China
- Prior art keywords
- rna
- puromycin
- sequence
- polypeptide
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063030056P | 2020-05-26 | 2020-05-26 | |
| US63/030,056 | 2020-05-26 | ||
| PCT/US2021/034131 WO2021242793A2 (en) | 2020-05-26 | 2021-05-26 | Nucleic acid artificial mini-proteome libraries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116249774A true CN116249774A (zh) | 2023-06-09 |
Family
ID=76859704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180048206.XA Pending CN116249774A (zh) | 2020-05-26 | 2021-05-26 | 核酸人工微型蛋白质组文库 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230203477A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4158014A2 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7854946B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230029673A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116249774A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021280261A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3185387A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021242793A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023034901A1 (en) | 2021-09-01 | 2023-03-09 | The Broad Institute, Inc. | Tumor avatar vaccine compositions and uses thereof |
| US12112833B2 (en) | 2020-02-04 | 2024-10-08 | 10X Genomics, Inc. | Systems and methods for index hopping filtering |
| US12168801B1 (en) * | 2020-07-02 | 2024-12-17 | 10X Genomics, Inc. | Hybrid/capture probe designs for full-length cDNA |
| US12580044B1 (en) | 2020-09-02 | 2026-03-17 | 10X Genomics, Inc. | Systems and methods for identifying cells that are antigen-specific for an immunogenic feature |
| US20250144198A1 (en) * | 2021-08-16 | 2025-05-08 | Duke University | Next generation vaccines comprising antigenic libraries and methods of making and using same |
| WO2023076733A1 (en) * | 2021-11-01 | 2023-05-04 | Dana-Farber Cancer Institute, Inc. | Biologically selected nucleic acid artificial mini-proteome libraries |
| EP4594488A1 (en) * | 2022-09-29 | 2025-08-06 | Twist Bioscience Corporation | Libraries for rna enrichment |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870790A (en) | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
| US4226859A (en) | 1979-06-07 | 1980-10-07 | Velsicol Chemical Corporation | Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids |
| ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| DE3583799D1 (de) | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US6991797B2 (en) | 1993-07-02 | 2006-01-31 | Statens Serum Institut | M. tuberculosis antigens |
| ES2243937T3 (es) | 1994-04-29 | 2005-12-01 | Baxter Healthcare S.A. | Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños. |
| US5705190A (en) | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
| US7255862B1 (en) | 1996-11-14 | 2007-08-14 | Connaught Technology Corporation | ALVAC/FIV constructs |
| WO1999014354A1 (en) | 1997-09-19 | 1999-03-25 | The Trustees Of The University Of The Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
| FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| WO2000006717A2 (en) | 1998-07-27 | 2000-02-10 | Genentech, Inc. | Improved transformation efficiency in phage display through modification of a coat protein |
| EP1101490B1 (en) | 1998-07-28 | 2005-04-13 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
| CA2334946A1 (en) * | 1998-08-17 | 2000-02-24 | Phylos, Inc. | Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular rna-protein fusion formation |
| US6955808B2 (en) | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
| US20040170955A1 (en) | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
| ES2376454T3 (es) | 2000-12-22 | 2012-03-14 | Grad, Carole, Legal Representative Of Howard, Kaplan | Librer�?as de expresión en fago de fragmentos vh humanos. |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| WO2005035751A1 (ja) * | 2003-10-15 | 2005-04-21 | Keio University | 高機能性タンパク質の迅速、高効率な選択法、それによって得られる高機能性タンパク質、およびその製造方法と利用方法 |
| EP2397490B1 (en) | 2004-07-16 | 2013-09-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV |
| EP2573185A3 (en) | 2005-02-16 | 2013-06-05 | Lentigen Corporation | Lentiviral vectors and their use |
| JP2011512326A (ja) | 2007-12-31 | 2011-04-21 | ナノコア セラピューティクス,インコーポレイテッド | 心不全の治療用のrna干渉 |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| LT2714071T (lt) | 2011-05-24 | 2019-10-10 | Biontech Rna Pharmaceuticals Gmbh | Individualizuotos vakcinos nuo vėžio |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| WO2018213803A1 (en) * | 2017-05-19 | 2018-11-22 | Neon Therapeutics, Inc. | Immunogenic neoantigen identification |
| WO2020018461A1 (en) * | 2018-07-16 | 2020-01-23 | The University Of Virginia Patent Foundation | Compositions and methods of diagnosis and treatment for neurological diseases |
-
2021
- 2021-05-26 JP JP2022573214A patent/JP7854946B2/ja active Active
- 2021-05-26 EP EP21740278.3A patent/EP4158014A2/en active Pending
- 2021-05-26 KR KR1020227045521A patent/KR20230029673A/ko active Pending
- 2021-05-26 AU AU2021280261A patent/AU2021280261A1/en active Pending
- 2021-05-26 WO PCT/US2021/034131 patent/WO2021242793A2/en not_active Ceased
- 2021-05-26 CA CA3185387A patent/CA3185387A1/en active Pending
- 2021-05-26 US US17/927,112 patent/US20230203477A1/en active Pending
- 2021-05-26 CN CN202180048206.XA patent/CN116249774A/zh active Pending
-
2026
- 2026-04-21 JP JP2026070113A patent/JP2026117232A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230029673A (ko) | 2023-03-03 |
| EP4158014A2 (en) | 2023-04-05 |
| JP2026117232A (ja) | 2026-07-14 |
| US20230203477A1 (en) | 2023-06-29 |
| JP7854946B2 (ja) | 2026-05-07 |
| WO2021242793A2 (en) | 2021-12-02 |
| WO2021242793A3 (en) | 2022-02-24 |
| JP2023528805A (ja) | 2023-07-06 |
| AU2021280261A1 (en) | 2023-01-19 |
| CA3185387A1 (en) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7854946B2 (ja) | 核酸人工ミニプロテオームライブラリー | |
| US12247214B2 (en) | Vaccinia viral vectors encoding chimeric virus like particles | |
| US8012490B2 (en) | Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents | |
| JP5933565B2 (ja) | 組み換え改変ワクシニアウイルスアンカラインフルエンザワクチン | |
| CN112979829B (zh) | 融合蛋白及其在制备靶向新冠病毒sars-cov-2的疫苗中的应用 | |
| KR20160030317A (ko) | 유전자 조작된 항체 유전자 발현 카세트를 갖는 미니서클 dna 재조합 모 플라스미드, 상기 발현 카세트를 갖는 미니서클 dna 및 용도 | |
| TW202229556A (zh) | 針對SARS-CoV-2之改良型DNA疫苗 | |
| JP2024535855A (ja) | Krasネオ抗原療法 | |
| WO1998048834A1 (en) | Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents | |
| JP2025534986A (ja) | Egfrワクチンカセット | |
| JP2012039877A (ja) | ユビキチン融合遺伝子およびそれを用いたdnaワクチン | |
| CN117004579B (zh) | 重组溶瘤牛痘病毒及其应用 | |
| CN121620389A (zh) | 一种针对MICA/B靶点的mRNA肿瘤疫苗 | |
| WO2023076733A1 (en) | Biologically selected nucleic acid artificial mini-proteome libraries | |
| WO2005026316A2 (en) | Alphavirus vaccines | |
| WO2004096288A2 (es) | Método para la obtencion de minicírculos replicativos de adn para transferencia génica o como inmunomoduladores. | |
| JP2025534300A (ja) | Ctaワクチンカセット | |
| WO2004050112A1 (en) | Intratumor administration of heat shock protein and its combination tumor therapy with cell toxin | |
| Muraro et al. | Molecular modification of idiotypes from B cell lymphomas for expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |